Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells

B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics. It can occur in any part of the body, accounting for more than 80% of all lymphomas. The present study aimed to construct bispecific...

Full description

Bibliographic Details
Main Authors: Yanlong Liu, Kexin Ao, Fuxiang Bao, Yi Cheng, Yanxia Hao, Huimin Zhang, Shan Fu, Jiaqi Xu, Qiyao Wu
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Vaccines
Subjects:
CD20
CD3
phage display technology
bispecific single-domain antibody
antitumor effect
Online Access:https://www.mdpi.com/2076-393X/10/8/1335

Internet

https://www.mdpi.com/2076-393X/10/8/1335

Similar Items